title: Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.
abstract: The guidelines for immunization of hematopoietic SCT (HSCT) recipients recommend three doses of antipneumococcal conjugate vaccine (PCV) from 3 to 6 months after transplant, followed by a dose of polysaccharide 23-valent (PPV23) vaccine at 12 months in the case of no GVHD or an additional PCV dose in the case of GVHD. Due to the lack of long-term data in the literature, there is no recommendation for boosts after 12 months. Our goal was to assess the maintenance of the immune response to pneumococcal vaccines in patients vaccinated 10 years ago according to current guidelines. Thirty surviving patients of the IDWP01 (Infectious Diseases Working Party 1) trial were assessed for antibody levels against the seven antigens of the PCV7 and against two of the PPV23-specific antigens. When compared with 24 months after transplant, the immune response did not significantly decrease but with important serotype-specific variability. There was no evidence that an additional dose of PPV23 given to 11/30 patients 2-11 years after transplant was beneficial. In long-term HSCT survivors with no or few GVHD vaccinated against Streptococcus pneumoniae according to the current guidelines, the specific immunity is not fully maintained a decade later. The optimal schedule of antipneumococcal vaccination in HSCT recipients after 12 months remains to be established.
authors: Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris-Est Créteil University, Créteil, France.
authors: C
authors: C
authors: Cordonnier
authors: EBMT Data and Study Office, Saint-Antoine Teaching Hospital, AP-HP; and UPMC Paris 6 University, INSERM UMR-S 893 Group 14, Paris Cedex 12, France.
authors: M
authors: M
authors: Labopin
authors: Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris-Est Créteil University, Créteil, France.
authors: C
authors: C
authors: Robin
authors: Service d'Hématologie-Greffe de Moelle, APHP Hôpital Saint-Louis; and Université Paris Diderot, Sorbonne Paris-Cité, Paris, France.
authors: P
authors: P
authors: Ribaud
authors: Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP) and Paris-Est Créteil University, Créteil, France.
authors: L
authors: L
authors: Cabanne
authors: Service d'Hématologie-Greffe de Moelle, APHP Hôpital Saint-Louis; and Université Paris Diderot, Sorbonne Paris-Cité, Paris, France.
authors: C
authors: C
authors: Chadelat
authors: Policlinico G.B. Rossi, Paediatric Haematology Oncology, Verona, Italy.
authors: S
authors: S
authors: Cesaro
authors: Department of Hematology, Karolinska University Hospital; and Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
authors: P
authors: 0000000282813245
authors: P
authors: Ljungman
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D000069443:Heptavalent Pneumococcal Conjugate Vaccine / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*; D055815:Young Adult
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine